ArticleInternational journal of pharmaceutics: X2026
Co-delivery of doxorubicin and quercetin with Angiopep-2 modified graphene oxide for targeted chemo-photothermal therapy of glioblastoma.
Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma multiforme (GBM) is an aggressive brain tumor with limited treatment options due to poor drug penetration across the blood-brain barrier (BBB). As combined treatment with doxorubicin and quercetin exhibited synergistic cytotoxic effects against U87 glioblastoma cells, graphene oxide (GO) can be employed to deliver these drugs, thereby enhancing their bioavailability during chemotherapy. GO can also serve as an efficient photothermal agent under near-infrared (NIR) irradiation. In this study, we functionalize GO with the Angiopep-2 peptide ligand to prepare a GOA nanocarrier. After co-loading quercetin and doxorubicin, the GOA/Q/D nanoplatform can enable BBB crossing/tumor targeting, pH-responsive drug delivery, and efficient NIR-mediated photothermal conversion for targeted chemo-photothermal therapy of GBM. Physicochemical characterization confirmed successful nanoparticle fabrication, favorable stability, and efficient drug loading and controlled drug release. Confocal microscopy and flow cytometry analyses indicate enhanced cellular uptake of GOA by U87 cells and intracellular doxorubicin accumulation. The integration of synergistic chemotherapy and NIR-induced photothermal therapy with GOA/Q/D resulted in significantly increased apoptosis and tumor cell death. In vivo studies confirmed Angiopep-2-mediated brain accumulation in healthy and tumor-bearing nude mice after intravenous administration. Therapeutic evaluation further demonstrated significantly inhibited tumor growth and prolonged survival in glioma-bearing mice treated with GOA/Q/D through intravenous injection plus NIR laser irradiation at the tumor site. Collectively, the integration of targeted delivery, synergistic dual-drug chemotherapy, and photothermal activation resulted in markedly improved therapeutic efficacy, underscoring the potential of chemo-photothermal therapy for the targeted treatment of glioblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.